Welcome to our dedicated page for Abbvie SEC filings (Ticker: ABBV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading about AbbVie’s sprawling drug pipeline, patent cliffs, and FDA milestones inside a 300-page 10-K can be daunting. Add tables that track Humira biosimilar erosion and footnotes on Allergan-related intangibles, and even seasoned analysts look for help. That’s why this page exists—AbbVie SEC filings explained simply, without losing the critical details investors need.
Stock Titan’s AI breaks down every document the moment it hits EDGAR. Whether you need an AbbVie annual report 10-K simplified for pipeline probability math, an AbbVie quarterly earnings report 10-Q filing summarizing segment sales, or an AbbVie 8-K material events explained after a surprise FDA letter, our platform highlights the numbers and narrative that move ABBV shares. Real-time alerts surface AbbVie Form 4 insider transactions real-time, turning raw data into context within minutes. The same engine powers deeper AbbVie earnings report filing analysis that links management commentary to model-ready metrics.
Investors often ask how to spot patent-expiration risk or track Botox Aesthetics revenue in SEC disclosures. Here’s where to look:
- Form 4—monitor AbbVie insider trading Form 4 transactions and AbbVie executive stock transactions Form 4 before key drug launches.
- 10-Q / 10-K—compare R&D spend vs. pipeline progress with AI-generated heat maps.
- DEF 14A—the AbbVie proxy statement executive compensation reveals incentives tied to new-drug approvals.
From “understanding AbbVie SEC documents with AI” to setting custom alerts for upcoming trials, Stock Titan equips you to act on the data, not just read it.
Harte Hanks (HHS) has filed a Form 4 revealing that General Counsel Robert T. Wyman received 25,000 restricted stock units (RSUs) on 2 June 2025 at a reference price of $4.55 per share. The RSUs vest in three equal annual tranches on each anniversary of the grant date, encouraging long-term retention and alignment with shareholder interests.
After the award, Wyman reports 27,217 directly held common shares and 33,334 unvested RSUs—25,000 from the new 2025 grant plus 8,334 remaining from a 12,500-share grant made on 4 Mar 2024. The RSUs are held indirectly by the company until they vest, and no derivative securities, option exercises or open-market transactions were disclosed.
The filing represents routine executive equity compensation rather than an outright purchase. Immediate cash outlay is zero, and the incremental dilution from 25,000 shares is expected to be negligible relative to the company’s total share count. While the grant reinforces incentive alignment, it is unlikely to have a material impact on Harte Hanks’ near-term valuation or trading dynamics.
Potbelly Corporation (PBPB) – Form 4 filing: President & CEO Robert D. Wright reported three Code F transactions on 06/30/2025. Code F denotes shares surrendered to the issuer to cover tax obligations arising from the vesting of previously granted restricted stock units (RSUs).
- Shares withheld: 1,004, 537 and 641, totaling 2,182 common shares at an indicated price of $12.25.
- Post-transaction ownership: 780,254 common shares held directly.
- Context: The surrendered shares represent tax-related withholding, not open-market sales, and reduce Mr. Wright’s stake by a small fraction relative to his overall holdings.
No derivative security activity was reported, and there were no purchases or sales for investment purposes. The filing is routine and conveys minimal impact on Potbelly’s share-count or insider ownership profile.
Potbelly Corporation (PBPB) – Form 4 filing: President & CEO Robert D. Wright reported three Code F transactions on 06/30/2025. Code F denotes shares surrendered to the issuer to cover tax obligations arising from the vesting of previously granted restricted stock units (RSUs).
- Shares withheld: 1,004, 537 and 641, totaling 2,182 common shares at an indicated price of $12.25.
- Post-transaction ownership: 780,254 common shares held directly.
- Context: The surrendered shares represent tax-related withholding, not open-market sales, and reduce Mr. Wright’s stake by a small fraction relative to his overall holdings.
No derivative security activity was reported, and there were no purchases or sales for investment purposes. The filing is routine and conveys minimal impact on Potbelly’s share-count or insider ownership profile.
FAQ
What is the current stock price of Abbvie (ABBV)?
What is the market cap of Abbvie (ABBV)?
What is AbbVie Inc.?
Which therapeutic areas does AbbVie focus on?
How does AbbVie generate revenue?
What differentiates AbbVie in the pharmaceutical industry?
How does AbbVie approach research and development?
What are some key products or portfolios of AbbVie?
How does AbbVie maintain quality and compliance?
What makes AbbVie a reliable choice for investors?
